Definitive Contract 75F40119C10152
Award Date 9/25/19
Potential Completion Date 4/4/25
Potential Value $831K
Federal Agency
Awardee
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Storrs, CT 06269, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $1,417,987.00 federal contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn). The contract is a Definitive Contract without a set-aside designation. The contract involves a comparative trial of different packaging components of an opioid packaging solution to evaluate their impact on opioid safety outcomes. UConn is working with Hartford Hospital and the UConn Health Center as subcontractors on this research project, which aims to identify...
- This is a $973,150.35 definitive, firm fixed price contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) for a study on the "Impact of Polymer Attributes on the Performance of In Situ Forming Implants." The contract has a completion date of September 9, 2023 and was awarded on March 6, 2020. UConn, a non-profit educational institution, will leverage its expertise in scientific research and specialized services to support this FDA study....
- This is a $1,530,889.00 definitive contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) to conduct a research study titled "Investigating the Impact of API Purity, Excipient Source and Manufacturing Process on Performance and Quality of Complex siRNA Lipid Nanoparticles". The contract has a performance period ending on September 21, 2027 and is a cost-type contract with no fee. UConn, a non-profit 1862 land-grant university, has...
- This is a definitive contract awarded by the Department of Health and Human Services Food and Drug Administration to the University of Connecticut for "Assessing Long-Acting Injectable Formulations Using In Vivo Imaging". The potential value of the contract is $1,131,742.00 and it has a completion date of September 29, 2024. The contract is not set aside for a specific business category. Under this contract, the University of Connecticut is conducting research and analysis on...
- The Food and Drug Administration awarded a $2.24 million firm fixed-price definitive contract to the Regents of the University of Michigan on September 12, 2024, to conduct research on stimulant and opioid use disorder trajectories and associated consequences in U.S. adults using a mosaic approach. The contract, which will be performed at the University of Michigan in Ann Arbor, Michigan, is scheduled for completion by September 29, 2028. This research aligns with FDA's public health mission and...
- The University of Connecticut has been awarded a definitive contract by the Department of Health and Human Services Food and Drug Administration to continue processing liposomal nanoparticles as reference materials for drug product development. With a potential value of $349,364, this time and materials contract does not have a set-aside designation and is to be completed by May 31, 2023. As the prime contractor, the University will utilize its expertise in nanotechnology and materials...
- This is a $355,000.00 firm fixed price Delivery Order awarded by the Department of Health and Human Services Agency for Healthcare Research and Quality to the University of Connecticut. The contract is for prehospital non-opioid pain management services by emergency medical services (EMS) providers. The award is under the Evidence-based Practice Centers V (EPC V) indefinite delivery/indefinite quantity (IDIQ) master contract, which allows the agency to procure research and evaluation services on...
- The University of Connecticut (UConn) was awarded a $1,310,263 cost-no-fee definitive contract by the Food and Drug Administration (FDA) to enhance and validate in vitro-in vivo correlation (IVIVC) methods for long-acting injectable drug products to accelerate their generic development. The contract is part of the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits research and development proposals across various areas to modernize regulatory science and support...
- The Department of Health and Human Services Food and Drug Administration awarded a definitive cost-no-fee contract to the University of Kentucky Research Foundation, a non-profit subsidiary of the University of Kentucky, for the OPIOID STUDY KENTUCKY PMWP64 project. The contract has a potential value of $2,045,989.00 and a completion date of July 16, 2022. This contract is not set aside for any specific business designation. The University of Kentucky Research Foundation has a history of federal...
- This is a firm fixed-price Blanket Purchase Agreement (BPA) call awarded by the Food and Drug Administration (FDA) to the Research Triangle Institute (RTI International), a prominent non-profit research organization. The contract is for "UNDERSTANDING OPIOID PRESCRIBING AND THE USE OF ADJUNCTS AND ALTERNATIVES TO THEM" under the FDA's QUICK TURNAROUND SOCIAL SCIENCE RESEARCH SERVICES BPA, with a total ceiling value of $728,402.00 and a period of performance through March 29, 2027. This...